Regeneron operates as a unique biopharmaceutical company built on proprietary platforms such as VelocImmune technology and the Regeneron Genetics Center, enabling rapid discovery of therapeutic candidates and efficient delivery of innovative medicines. The company's platform-driven approach delivered 14 internally discovered approvals over the past 15 years, averaging roughly one major approval annually. 2026 is framed as a pivotal year, with multiple regulatory filings, clinical milestones, and new product launches on the horizon.
Cyborg Score Rationale
Dupixent full-year 2025 global net sales increased 26% to $17.8 billion, driving strong collaboration revenue. Fourth-quarter 2025 net sales of Eylea HD and Eylea reached upwards of $1.1 billion in the U.S., with Eylea HD showing growth of 66% year-over-year. However, concentrated product exposure, competitive pressure in ophthalmology and ongoing US pricing scrutiny remain key risks.
Top Insights
Dupixent achieved $17.8 billion in 2025 sales with 26% annual growth, solidifying its blockbuster status across immunology franchises.
CEO emphasized robust pipeline across multiple therapeutic areas with $6 billion in 2026 R&D investment supplemented by $7 billion in capital expenditures, signaling aggressive innovation agenda.
2026 will feature 18 additional Phase 3 studies with cumulative target enrollment of approximately 35,000 patients, supporting next-generation product development.
January 2026 collaboration with Tessera Therapeutics for gene editing therapy development became effective, expanding therapeutic modalities beyond traditional antibodies.
Named Competitors
Dupixent — Leading immunology blockbuster for eczema, asthma, and atopic dermatitis
EYLEA HD — High-dose anti-VEGF therapy for retinal diseases with flexible dosing
Libtayo — Immunotherapy for cutaneous squamous cell carcinoma and other cancers
Imfinzi — Anti-PD-L1 checkpoint inhibitor competing in immuno-oncology
Avastin — Anti-VEGF therapy competing in ophthalmology market
Recent Developments
(January 2026) Collaboration agreement with Tessera Therapeutics for alpha-1 antitrypsin deficiency gene editing therapy became effective
(January 2026) EYLEA HD approved by FDA for macular edema following retinal vein occlusion with monthly dosing flexibility; prefilled syringe decision expected Q2 2026
(January 2026) Libtayo approved by FDA and EC as first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma
(December 2025) Full year 2025 revenues reached $14.3 billion with Dupixent sales of $17.8 billion (+26% YoY)
Open the full interactive Regeneron Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.